首页|期刊导航|浙江中医药大学学报|基于UPLC-Q-Orbitrap HRMS、网络药理学与SPR的小儿止哮平喘颗粒抗哮喘机制研究

基于UPLC-Q-Orbitrap HRMS、网络药理学与SPR的小儿止哮平喘颗粒抗哮喘机制研究OA

Study on the Anti-asthma Mechanism of Xiao'er Zhixiao Pingchuan Granules Based on UPLC-Q-Orbitrap HRMS,Network Pharmacology and SPR

中文摘要英文摘要

[目的]联合运用超高效液相色谱-四极杆轨道离子阱高分辨质谱(ultra-performance liquid chromatography-quadrupole orbitrap high-resolution mass spectrometry,UPLC-Q-Orbitrap HRMS)、网络药理学、分子对接、表面等离子共振(surface plasmon resonance,SPR)技术及动物实验,探究小儿止哮平喘颗粒治疗支气管哮喘(bronchial asthma,BA)的药效物质基础及作用机制.[方法]首先,采用UPLC-Q-Orbitrap HRMS鉴定小儿止哮平喘颗粒的化学成分及入血移行成分;其次,运用网络药理学预测移行成分治疗BA的潜在靶点与通路;进而,通过分子对接和SPR技术验证活性成分与核心靶点的结合活性;最后,通过哮喘小鼠模型和免疫印迹实验对关键靶点蛋白表达进行验证.[结果]共鉴定出小儿止哮平喘颗粒112个化合物和79个血清移行成分.网络药理学分析提示,汉黄芩素、丹参酮ⅡA等为核心活性成分,其作用可能与磷脂酰肌醇3-激酶/蛋白激酶B(phosphoinositide 3-kinase/protein kinase B,PI3K-Akt)、丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)及瞬时受体电位(transient receptor potential,TRP)等信号通路有关.分子对接和SPR实验证实丹参酮ⅡA与神经生长因子(nerve growth factor,NGF)蛋白具有中等亲和力.动物实验结果表明,小儿止哮平喘颗粒能显著抑制哮喘小鼠肺组织和背根神经节中NGF、原肌球蛋白受体激酶A(tropomyosin receptor kinase A,TrkA)、瞬时受体电位通道V1(transient receptor potential vanilloid 1,TRPV1)、P物质(substance P,SP)及肥大细胞相关G蛋白偶联受体X2(mas-related G protein-coupled receptor X2,MRGPRX2)的蛋白表达,并抑制p38丝裂原活化蛋白激酶(p38 MAPK)的磷酸化.[结论]小儿止哮平喘颗粒可能通过调控NGF/TrkA/TRPV1/SP/MRGPRX2信号轴,减轻神经免疫源性炎症,从而缓解哮喘症状.

[Objective]To analyze the material basis and mechanism of Xiao'er Zhixiao Pingchuan Granules on bronchial asthma(BA)through ultra-performance liquid chromatography-quadrupole orbitrap high-resolution mass spectrometry(UPLC-Q-Orbitrap HRMS),network pharmacology,molecular docking and surface plasmon resonance(SPR)technology,combined with animal experiments.[Methods]First,UPLC-Q-Orbitrap HRMS method was used to detect the chemical components and migrating components of Xiao'er Zhixiao Pingchuan Granules;secondly,using network pharmacology to predict potential targets and pathways for the treatment of BA by migrating components;Then,the binding activity between the active ingredients and the core targets was validated using molecular docking and SPR techniques;Finally,the expression of key target proteins was confirmed through an asthma mouse model and western blot analysis.[Results]A total of 112 compounds and 79 serum migrating components were identified in Xiao'er Zhixiao Pingchuan Granules.Network pharmacology analysis indicated that wogonin and tanshinone ⅡA were the core active ingredients,and their effects might be associated with signaling pathways such as phosphoinositide 3-kinase/protein kinase B(PI3K-Akt),mitogen-activated protein kinase(MAPK),and transient receptor potential(TRP).Molecular docking and SPR assays confirmed that tanshinone ⅡA exhibited moderate binding affinity to nerve growth factor(NGF).Animal experimental results showed that Xiao'er Zhixiao Pingchuan Granules significantly inhibited the protein expression of NGF,tropomyosin receptor kinase A(TrkA),transient receptor potential vanilloid 1(TRPV1),substance P(SP),and mas-related G protein-coupled receptor X2(MRGPRX2)in the lung tissue and dorsal root ganglia of asthmatic mice,and also suppressed the phosphorylation of p38 mitogen-activated protein kinase(p38 MAPK).[Conclusion]Xiao'er Zhixiao Pingchuan Granules may alleviate asthmatic symptoms by regulating the NGF/TrkA/TRPV1/SP/MRGPRX2 signaling axis and ameliorating neuroimmune-derived inflammation.

张丽;刘南阳;高蕊;安子萌;曹唯仪;彭征屏;万通

中国中医科学院西苑医院 北京 100091中国中医科学院西苑医院 北京 100091中国中医科学院西苑医院 北京 100091中国中医科学院西苑医院 北京 100091中国中医科学院西苑医院 北京 100091中国中医科学院西苑医院 北京 100091中国中医科学院西苑医院 北京 100091

医药卫生

小儿止哮平喘颗粒支气管哮喘质谱网络药理学SPR神经免疫TRPV1MRGPRX2

Xiao'er Zhixiao Pingchuan Granulesbronchial asthmamass spectrometrynetwork pharmacologySPRneuroimmunityTRPV1MRGPRX2

《浙江中医药大学学报》 2026 (7)

833-849,17

中国中医科学院西苑医院能力提升项目(XYZX0101-39、XYZX0405-19)中国中医科学院科技创新工程项目(CI2021A04701)Hospital Capability Enhancement Project of Xiyuan Hospital,CACMS(XYZX0101-39,XYZX0405-19)Major Project of Scientific and Technological Innovation Engineering of CACMS(CI2021A04701)

10.16466/j.issn1005-5509.2026.07.003

评论